Descriptor: "*PROGRAMMED death-ligand 1" / Journal: value in health / Publisher: elsevier b.v. / Topic: metastasis - Searchworks@Jio Institute Digital Library Search Results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Your search keyword '"*PROGRAMMED death-ligand 1"' showing total 6 results

Start Over Descriptor "*PROGRAMMED death-ligand 1" Topic metastasis Journal value in health Publisher elsevier b.v.

6 results on '"*PROGRAMMED death-ligand 1"'

1. EE84 Cost-Effectiveness of Pembrolizumab Plus Nab-paclitaxel in Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) Whose Tumors Expressed Pd-L1 (CPS ≥10) in Colombia.

Author: Urrego-Reyes, J., Lopez, C., Marrugo A., C., Velasco, J.S., Singla, P., Gotarkar, S., Huang, M., and Haiderali, A.
Subjects: *TRIPLE-negative breast cancer, *PACLITAXEL, *PROGRAMMED death-ligand 1, *COST effectiveness, *METASTASIS, *TUMORS
Published: 2023
Full Text: View/download PDF

2. EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective.

Author: Benyounes, K, Delzard, M, Le Lay, K, Bianic, F, and Bougeard, C
Subjects: *ATEZOLIZUMAB, *BUDGET, *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *PROGRAMMED cell death 1 receptors, *METASTASIS
Published: 2022
Full Text: View/download PDF

3. EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States.

Author: Huang, M, Fasching, P, Haiderali, A, Pan, W, Gray, E, Zhou, J, Hu, PH, Le Bailly De Tilleghem, C, Cappoen, N, Chaudhuri, M, and O'Shaughnessy, J
Subjects: *COST effectiveness, *PROGRAMMED death-ligand 1, *CANCER chemotherapy, *METASTASIS, *PEMBROLIZUMAB
Published: 2022
Full Text: View/download PDF

4. EE44 Cost-Effectiveness of Pembrolizumab in First-Line Treatment of PD-L1 Positive Persistent, Recurrent, or Metastatic Cervical Cancer.

Author: Nedzesky, J and Veenstra, D
Subjects: *PEMBROLIZUMAB, *CERVICAL cancer, *METASTASIS, *PROGRAMMED death-ligand 1, *COST effectiveness, *THERAPEUTICS
Published: 2022
Full Text: View/download PDF

5. POSA108 A Budget Impact Analysis of Atezolizumab Monotherapy for First Line Treatment of Patients with PD-L1 High Metastatic NSCLC in Italy.

Author: Pradelli, L, Bellone, M, Heaton, E, Celik, H, Caputo, A, and Belfiore, M
Subjects: *ATEZOLIZUMAB, *PROGRAMMED death-ligand 1, *NON-small-cell lung carcinoma, *METASTASIS, *THERAPEUTICS
Published: 2022
Full Text: View/download PDF

6. PCN148 The Clinical and Economic IMPACT of PD-L1 SP142 ASSAY Using Atezolizumab + Npaclitaxel in the Pathway of Patients with Metastatic or Advanced Triple Negative Breast Cancer.

Author: Cattelino, L., Piccolo, F., and Mauti, R.
Subjects: *TRIPLE-negative breast cancer, *PROGRAMMED cell death 1 receptors, *ATEZOLIZUMAB, *PROGRAMMED death-ligand 1, *ECONOMIC impact, *METASTASIS
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results